The National Institutes of Health (NIH) is offering this grant to encourage basic biologic research into chemotherapy-induced peripheral neuropathy (CIPN). This grant aims to stimulate neuroscience researchers to apply their expertise from other neuropathies to understand nerve damage caused by cancer treatments. Its purpose is to uncover the mechanisms of neuronal damage and identify critical targets for CIPN initiation and maintenance. Preclinical research on both neuropathic pain and neurosensory symptoms like paresthesias is invited. The ultimate goal is a molecular understanding of CIPN to enable rational development of interventions for its treatment or prevention.
Opportunity ID: 138315
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PA-12-082 |
| Funding Opportunity Title: | Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.399 — Cancer Control |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 17, 2012 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | May 07, 2015 |
| Current Closing Date for Applications: | May 07, 2015 |
| Archive Date: | Jun 07, 2015 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Independent school districts Small businesses County governments Special district governments Native American tribal governments (Federally recognized) State governments Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapy-induced peripheral neuropathy (CIPN). The majority of acquired peripheral neuropathy research has focused on diabetic and inherited diseases; this FOA intends to stimulate neuroscience researchers to apply their expertise from studying these other neuropathies to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets instrumental to CIPN initiation and maintenance. Preclinical research that focuses not only on peripheral neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anesthesias is invited. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevention CIPN. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PA-12-082.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| ADOBE-FORMS-B2 | ADOBE-FORMS-B2 | PKG00091910 | May 05, 2012 | Sep 24, 2013 | View | |
| FORMS-C | Use for due dates after 9/24/2013 | PKG00180587 | Sep 08, 2013 | May 07, 2015 | View |
Package 1
Mandatory forms
138315 RR_SF424_1_2-1.2.pdf
138315 PerformanceSite_1_4-1.4.pdf
138315 RR_OtherProjectInfo_1_3-1.3.pdf
138315 RR_KeyPersonExpanded_1_2-1.2.pdf
138315 PHS398_CoverPageSupplement_1_4-1.4.pdf
138315 PHS398_ResearchPlan_1_3-1.3.pdf
138315 PHS398_Checklist_1_3-1.3.pdf
Optional forms
138315 RR_SubawardBudget30-1.2.pdf
138315 PHS398_ModularBudget_1_2-1.2.pdf
138315 RR_Budget-1.1.pdf
138315 PHS_CoverLetter_1_2-1.2.pdf
Package 2
Mandatory forms
138315 RR_SF424_2_0-2.0.pdf
138315 PHS398_ResearchPlan_2_0-2.0.pdf
138315 PHS398_CoverPageSupplement_2_0-2.0.pdf
138315 RR_KeyPersonExpanded_2_0-2.0.pdf
138315 RR_OtherProjectInfo_1_3-1.3.pdf
138315 PerformanceSite_2_0-2.0.pdf
Optional forms
138315 RR_SubawardBudget30_1_3-1.3.pdf
138315 PlannedReport-1.0.pdf
138315 PHS398_CumulativeInclusionReport-1.0.pdf
138315 PHS398_ModularBudget_1_2-1.2.pdf
138315 RR_Budget_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
